Mouse IFN‑ beta Antibody

Name: Mouse IFN‑ beta Antibody
Brand: R&D Systems
SKU: MAB8234
Price: 479 USD
Availability: InStock

R&D Systems | Catalog # MAB8234

Submit a review

Citations (2)

Product Documents

Recombinant Monoclonal Antibody.

View Available Conjugates

100% Guarantee

Product Specifications
Scientific Data
Applications
Preparation & Storage
Calculators
Background
Product Documents
Specific Notices
Research Areas
Related Blogs

Key Product Details

Species Reactivity

Validated:

Mouse

Cited:

Mouse, Transgenic Mouse

Applications

Validated:

Neutralization

Cited:

In vivo assay

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Rabbit IgG Clone # 1176D

View all IFN-beta Primary Antibodies »

Product Specifications

Immunogen

Human embryonic kidney cell line HEK293-derived mouse IFN‑ beta
Ile22-Asn182
Accession # P01575

Specificity

Detects mouse IFN‑ beta in direct ELISAs.

Clonality

Monoclonal

Host

Rabbit

Isotype

IgG

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Mouse IFN‑ beta Antibody

IFN‑ beta Inhibition of Viral-induced Cytopathy and Neutralization by Mouse IFN‑ beta Antibody.

Recombinant Mouse IFN-beta (Catalog # 8234-MB) reduces the viral-induced cytopathy in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line) as measured by Resazurin (Catalog # AR002). Inhibition of viral activity elicited by Recombinant Mouse IFN-beta (10 pg/mL) is neutralized (green line) by increasing concentrations of Rabbit Anti-Mouse IFN-beta Monoclonal Antibody (Catalog # MAB8234). The ND₅₀ is typically 0.25-1.25 µg/mL.

Applications for Mouse IFN‑ beta Antibody

Application

Recommended Usage

Neutralization

Measured by its ability to neutralize IFN‑ beta inhibition of viral-induced cytopathy in the L‑929 mouse fibroblast cell line. The Neutralization Dose (ND₅₀) is typically 0.25-1.25 µg/mL in the presence of 10 pg/mL Recombinant Mouse IFN‑ beta.

Formulation, Preparation, and Storage

Purification

Protein A or G purified from cell culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: IFN-beta

Interferon beta (IFN-beta ), also known as fibroblast IFN, is a secreted, approximately 22 kDa member of the type I interferon family of molecules (1). Mature mouse IFN-beta shares 75% and 47% amino acid sequence identity with the rat and human proteins, respectively. Fibroblasts are the major producers of IFN-beta, but it can also be produced by dendritic cells, macrophages, and endothelial cells in response to pathogens (2). It is transcriptionally regulated by TRAF3, IRF3, IRF7, and NF-kappa B (3, 4). IFN-beta -deficient mice show increased susceptibility to experimental autoimmune encephalomyelitis (EAE), a disease model of human multiple sclerosis (MS) (5). Furthermore, IFN-beta has been shown to suppress the Th17 cell response in both MS and EAE and has commonly been used as a treatment for MS (6-10). IFN-beta can additionally induce the expression of the anti-inflammatory cytokine IL-10 (11).

References

González-Navajas, J.M. et al. (2012) Nat. Rev. Immunol. 12:125.
Reder, A.T. and X. Feng (2013) Front. Immunol. 4:281.
Schafer, S.L. et al. (1998) J. Biol. Chem. 273:2714.
Häcker, H. et al. (2006) Nature 439:204.
Teige, I. et al. (2003) J. Immunol. 170:4776.
Shinohara, M.L. et al. (2008) Immunity 29:68.
Guo, B. et al. (2008) J. Clin. Invest. 118:1680.
Ramgolam, V.S. and S. Markovic-Plese (2010) Endocr. Metab. Immune Disord. Drug Targets 10:161.
Martín-Saavedra, F.M. et al. (2008) Mol. Immunol. 45:4008.
Inoue, M. and M.L. Shinohara (2013) Immunology 139:11.
Wang, H. et al. (2011) J. Immunol 186:675.